



(51) International Patent Classification:

A61K 35/74 (2015.01) A61K 9/06 (2006.01)  
A61K 8/99 (2017.01) A61P 17/10 (2006.01)

(21) International Application Number:

PCT/US2019/051156

(22) International Filing Date:

13 September 2019 (13.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/730,999 13 September 2018 (13.09.2018) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 5th Floor, Oakland, CA 94607-52000 (US).

(72) Inventors: **GALLO, Richard, L.**; 3036 Serbian Place, San Diego, CA 92117 (US). **NAKATSUJI, Teruaki**; 11324 Squamish Road, San Diego, CA 92126 (US). **O'NEILL, Alan, O.**; 4258 Noyes Street, San Diego, CA 92109 (US).

(74) Agent: **BAKER, Jr., Joseph, R.**; Gavrilovich, Dodd & Lindsey LLP, 4370 La Jolla Village Drive, Suite 303, San Diego, CA 92122 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BACTERIOTHERAPY AGAINST PROPIONIBACTERIUM ACNES FOR THE TREATMENT OF ACNE




FIG. 5E

(57) Abstract: The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition useful for treating acne.

**BACTERIOTHERAPY AGAINST PROPRIONIBACTERIUM ACNES FOR THE TREATMENT  
OF ACNE**

**STATEMENT AS TO FEDERALLY SPONSORED RESEARCH**

[0001] This invention was made with Government support under Grant Nos. AI118816, AR067547, AI117673-02, AR06781, and AI052453 awarded by the National Institutes of Health. The Government has certain rights in the invention.

**CROSS REFERENCE TO RELATED APPLICATIONS**

[0002] This application claims priority under 35 U.S.C. §119 from Provisional Application Serial No. 62/730,999, filed September 13, 2018, the disclosures of which are incorporated herein by reference.

**INCORPORATION BY REFERENCE OF SEQUENCE LISTING**

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on September 13, 2019, is named 00015-354W01\_SL.txt and is 12,125,812 bytes in size.

**TECHNICAL FIELD**

[0004] The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition and formulations to treat acne.

**BACKGROUND**

[0005] The human skin harbors diverse microbial communities which constitute important element of innate immune barrier to defend the host from pathogens.

**SUMMARY**

[0006] The disclosure provides a topical probiotic composition comprising, consisting essentially of or consisting of a microorganism selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

[0007] The disclosure also provides a postbiotic composition comprising a fermentation extract of a probiotic composition comprising, consisting essentially of or consisting of a microorganism selected from the group consisting of *S. capitis*

N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

[0008] The disclosure also provides a pharmaceutical composition comprising a probiotic of postbiotic of the disclosure and a pharmaceutically acceptable carrier.

[0009] The disclosure also provides a method of treating a dermatological disorder associated with *C. acnes* (*P. acnes*) comprising administering an effective amount of a composition of or pharmaceutical composition of the disclosure that inhibits *C. acnes* growth, viability or activity. In one embodiment, the dermatological disorders is selected from the group consisting of acne, chronic blepharitis and endophthalmitis. In another or further embodiment, the administering is by topical application.

[0010] The disclosure also provides a topical composition consisting of one or more bacteria selected from *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and a carrier. In one embodiment, the topical composition comprises a lotion, tincture, cream or ointment.

[0011] The disclosure also provides a composition comprising a cell-free fermentation extract obtain from *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 or any combination thereof.

[0012] The disclosure provides strains of CoNS that are potent inhibitors of *Propionibacterium acnes* (*P. acnes*), a Gram positive anaerobic bacterium that mostly resides in the hair follicles of the skin. The disclosure provides 14 strains of CoNS that produce potent antimicrobial activity against *P. acnes* (Table 1). These CoNS strains were screened and isolated from human skin and were from diverse species, including *Staphylococcus epidermidis*, *Staphylococcus hominis*, *Staphylococcus warneri*, *Staphylococcus capitis* and *Staphylococcus lugdinensis*. These anti-*P. acnes* CoNS strains can be used for bacterial therapy targeting *P. acnes* to treat patients with inflammatory acne.

[0013] The disclosure provides methods and compositions useful for treating acne and *C. acnes* infection.

[0014] The disclosure provides a topical probiotic composition comprising, consisting essentially of or consisting of a

microorganism selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

**[0015]** The disclosure also provides a postbiotic composition comprising a fermentation extract of a probiotic composition comprising, consisting essentially of or consisting of a microorganism selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

**[0016]** The disclosure also provides pharmaceutical composition of either of the above in combination with a pharmaceutically acceptable carrier.

**[0017]** The disclosure provides composition comprising a thickened topical formulation of one or more probiotic bacterial strains and optionally, a prebiotic compound, a protectant, humectant, emollient, abrasive, salt, and/or surfactant; wherein the one or more probiotic bacterial strain comprises one or more bacterial strains are selected from the group consisting of *S. capitis*, *S. epidermidis* and any combination thereof; wherein the composition is formulated for the topical treatment of disorders of dysbiosis of the skin, scalp, or mucosae; and wherein the composition inhibits the growth of *C. acnes*. In one embodiment, the one or more probiotic bacterial strain are selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* and any combination thereof. In another or further embodiment, the one or more probiotic bacterial of *S. epidermidis* are selected from the group consisting of *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof. In still another embodiment, the one or more probiotic bacterial strains comprises *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof. IN another embodiment, each probiotic bacterial strain inhibits *C. acnes* growth. In still another or further embodiment, the one or more probiotic bacterial strains is provided in a live form. In yet another embodiment, the one or more probiotic bacterial strains is provided in a lyophilized or freeze-dried or

spray dried form. In a further embodiment, the probiotic bacterium can be reconstituted into a live form.

**[0018]** The disclosure also provides a method of treating skin or mucosal infections, atopic dermatitis, psoriasis, mastitis, acne, or other disorders related to skin dysbiosis in humans or other mammals by applying to the skin or mucosa an effective amount of the composition of composition or formulation described herein to a subject in need thereof. In one embodiment, the composition is applied topically. In another or further embodiment, the composition is formulated as a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.

**[0019]** The disclosure also provides a method of treating a dermatological disorder associated with *C. acnes* comprising administering an effective amount of a composition as described herein or pharmaceutical composition thereof which inhibits *C. acnes* growth, viability or activity. In one embodiment, the dermatological disorders is selected from the group consisting of acne, chronic blepharitis and endophthalmitis. In another or further embodiment, the administering is by topical application.

**[0020]** The disclosure also provides a topical composition consisting of one or more bacteria selected from *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and a carrier. In one embodiment, the carrier forms a lotion, tincture, cream or ointment.

**[0021]** The disclosure also provides a composition comprising a cell-free fermentation extract obtain a culture of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 or any combination thereof. The disclosure also provides a pharmaceutical composition comprising a cell-free fermentation extract obtain a culture of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 or any combination thereof and a pharmaceutically acceptable carrier.

**[0022]** The disclosure also provides a formulation for topical application comprising a cell-free fermentation extract obtain a culture of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 or any combination

thereof and a pharmaceutically acceptable carrier. In one embodiment, the composition or formulation comprises a plurality of phenol soluble modulin peptides (PSMs). In another or further embodiment, the PSM is a PSM selected from the group consisting of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof. In another embodiment, the composition or formulation comprises PSM $\beta$ 1, 3, 4 and 6. In a further embodiment, the formulation comprises a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.

**[0023]** The disclosure provides a method of treating a dermatological disorder associated with *C. acnes* comprising administering an effective amount of a composition or formulation of the disclosure which inhibits *C. acnes* growth, viability or activity.

**[0024]** The disclosure also provides a method of diagnosing a skin disease or disorder comprising measuring the amount of PSM $\beta$  in a sample from the skin of a subject, wherein the measurement determines the level of PSM selected from the group consisting of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof and comparing the levels to a normal control level of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof, wherein a level that is lower in the sample is indicative of a skin disease or disorder. In one embodiment, the skin disease or disorder is a *C. acnes* infection.

**[0025]** The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

#### DESCRIPTION OF DRAWINGS

**[0026]** **Figure 1A-B** shows domain architecture of predicted NRPS cluster in *S. capitis* N030\_E12. **A.** Several genes contain domains involved in synthesis of antimicrobial peptides. AMP-binding domains suggest acyl CoA synthetase activity upstream of an acyl carrier protein (ACP). The condensation domain is found in many multi-domain enzymes that synthesize peptide antibiotics, catalyzing a condensation reaction to form peptide bonds in non-ribosomal peptide biosynthesis. Nicotinamide adenine dinucleotide (NAD)-binding domain is also present which contains the short chain

dehydrogenases/reductases (SDR) superfamily domain. **B.** Results of sequence comparison of the *S. capitis* gene containing a condensation domain against known reference genes using Natural Product Domain Seeker (NaPDos) - a bioinformatic tool for the rapid detection and analysis of secondary metabolite genes in bacteria, revealing similarity with known antimicrobial products.

[0027] **Figure 2A-B** shows domain architecture of predicted *trans*-AT PKS cluster in *S. epidermidis* strains. **A.** Polyketide synthases (PKS) polymerize simple fatty acids into a large variety of natural products, called polyketides. Notable domains within the PKS enzymes include dehydratase (DH) and ketoreductase (KR). **B.** Results of sequence comparison of the *S. epidermidis* PKS\_KS-containing gene against known reference genes using NaPDos revealing similarity with known antimicrobial products.

[0028] **Figure 3** shows growth inhibition of *C. acnes* in sterile supernatant of multiple different *C. acnes* strains. Growth of lesional acne-associated strains (*C. acnes* 25 and 26) and a health-associated strain (*C. acnes* 27) was measured by OD<sub>600</sub> after 72 hours growth in 100% sterile supernatant of indicated *C. acnes* strains grown for 7 days in RCM medium. Supernatant of health-associated strains *C. acnes*\_UCSD\_HI12 and *C. acnes*\_UCSD\_HI30 (single locus sequence type D1 and A5, respectively) were potent inhibitors of *C. acnes* growth and chosen as attractive candidates for acne biotherapy (indicated by arrows and boxes).

[0029] **Figure 4** shows antimicrobial activity of 24 stains of coagulase negative staphylococcus isolated from the normal human skin against 2 strains of *Propionibacterium acnes* (ATCC6919 and ATCC29322). Anti-*P. acnes* activity of each CoNS clone was measured by Radial Diffusion Assay. Briefly, 5 µl of overnight culture of each CoNS clone (white spot in each square) was spotted on a Bullucella Broth agar plate containing indicated strain of *P. acnes*. The agar plate was incubated under an anaerobic condition at 37 °C for 72 hours to let *P. acnes* grow. The black area represents zone of growth inhibition of *P. acnes* (see arrows). Each number represents key# of CoNS strains listed in Table A.

[0030] **Figure 5A-F** shows function screening method and results to identify antimicrobial CoNS species that target *C. acnes*. **(A)**

Schematic for the high-throughput antimicrobial functional screen, outlining the collection and selection of CoNS strains from two distinct healthy skin sites and assays to detect antimicrobial activity against *C. acnes* via coculture on agar or growth in sterile conditioned supernatant of CoNS. **(B,C)** Growth of *C. acnes* after 24 h incubation in 50% sterile filtered supernatant of the CoNS strain library (B) or growth of *C. acnes* with CoNS coculture in agar (C). The most potent antimicrobial CoNS isolate was selected and identified as *S. capitis* E12 (red), whilst *S. hominus* A9 (blue) did not exhibit activity against *C. acnes*. **(D)** Table showing the inhibitory activity of *S. capitis* E12 and *S. hominus* A9, against several skin commensal and pathogen strains, including several strains of *C. acnes* isolated from healthy and acne skin, as measured by size of zone inhibition by antimicrobial agar assay (+ small, ++ medium, +++ large). **(E)** Growth of *C. acnes* C2 after 24 h incubation in media alone or increasing concentrations of sterile supernatant of *S. capitis* E12 or *S. hominus* A9. **(F)** Survival of several species of staphylococci and *C. acnes* after 24 h post-treatment with increasing concentrations of sterile *S. capitis* E12 supernatant, as measured by the number of surviving CFU plated onto the appropriate selective agar.

**[0031]** **Figure 6A-H** shows purification and identification of *S. capitis* E12 antimicrobial peptides. **(A,B)** 60% ammonium sulphate precipitated supernatant of *S. capitis* E12 was loaded onto a HLB column and eluted by 80% acetonitrile. The HLB eluant was loaded onto a C8 cartridge and eluted by 50% acetonitrile. Fractions were measured for activity against *C. acnes* by agar assay **(A)** and liquid culture **(B)**. **(C)** Silver stain of the total protein content of *S. capitis* treated or untreated supernatant and the SPE flow-through and eluted fractions. **(D)** HPLC purification of *S. capitis* supernatant identified several peptide peaks, of which a single fraction (21) was identified as having anti-*C. acnes* activity **(E)**. Fraction 21 was pooled from five separate HPLC runs and purified by second step HPLC resulting in two fractions (15 and 16) with anti-*C. acnes* activity **(G)**. MS was performed for active fractions 15 and 16 including four non-active fractions as controls and identified four distinct PSM $\beta$  peptides as likely candidates for antimicrobial

peptides. **(H)** Results of the top 8 peptide hits from MS detection of HPLC purified active fractions (15 and 16) and control non-active fractions (13,14, 17 and 18) revealing peptides corresponding to 'antibacterial protein' and later confirmed as PSM $\beta$  peptides.

**[0032]** **Figure 7A-D** shows whole genome sequencing of *S. capitis* E12 reveals sequence and predicted properties of the PSM $\beta$  peptides. **(A)** Schematic highlighting the *S. capitis* E12 genetic cluster containing six gene-encoding PSM $\beta$  peptides (PSM $\beta$ 1-6). **(B)** Multiple sequence alignment (ClustalW) of all six PSM $\beta$  peptides, including the predicted charge for each peptide (SEQ ID NOs:9437, 9439, 9441, 9443, 9445, 9447). **(C)** Absence of antimicrobial activity against *C. acnes* during live coculture or sterile supernatant exposure with ATCC *S. capitis* strains 35661 and 27840 that lack PSM $\beta$  genes. **(D)** Representative helical wheel plot (Heliquest) of PSM $\beta$ 1 indicating a predicted amphipathic structure.

**[0033]** **Figure 8A-F** shows preclinical efficacy of PSM $\beta$  peptides and extract as a therapeutic for acne vulgaris. **(A)** Inhibition of *C. acnes* C2 after 72 h culture in the presence of *S. capitis* E12 extract or with synthetic peptides PSM $\beta$ 1, PSM $\beta$ 4, PSM $\beta$ 6 individually or in combination of all three **(B)** Growth of *C. acnes* C2 cultured for 72 h in the presence of *S. capitis* extract or with several different antibiotics. **(C)** Cytotoxicity of NHEKs treated with *S. capitis* E12, *S. epidermidis* C5, *S. epidermidis* 1457 and *S. capitis* 35561 supernatant for 24 h, presented as the percentage of maximal LDH release. **(D)** Visual representation of erythema on the back skin of SKH1 mouse after inoculation with  $1 \times 10^7$  CFU of *S. capitis* E12, *S. epidermidis* C5, *S. epidermidis* 1457 and *S. capitis* 35661 for 24 h. **(E)** Total number of surviving CFU of *C. acnes* C2 on ex vivo pig skin explants 24 h post-treatment with *S. capitis* E12 extract (10 mg/mL) or PBS control. **(F)** Total number of surviving CFU of *C. acnes* C2 on SKH1 mouse back skin 24 h post-treatment with *S. capitis* E12 extract (10 mg/mL) or PBS control.

**[0034]** **Figure 9A-C** shows characterization of the biological nature of the *S. capitis* active molecule(s). **(A)** Growth of *C. acnes* C2 was measured in liquid culture with or without *S. capitis* E12 supernatant untreated, boiled at 90°C for 15 mins or separated through 10 kDa or 3 kDa MWCO columns into retained or flow-through

fractions. **(B)** *S. capitis* E12 and control *S. hominus* A9 supernatant was subjected to papain or proteinase K proteolytic digestion (200 µg/ml) for 45 min at 37°C and inoculated onto *C. acnes*-containing agar to measure antimicrobial activity. **(C)** CoNS supernatant was subjected to precipitation in different saturation amounts of ammonium sulphate, and antimicrobial activity of each precipitate was measured by growth of *C. acnes* C2 72 h post-treatment.

**[0035]** **Figure 10A-B** shows PSMβ peptides are extracted by n-Butanol treatment of *S. capitis* E12 supernatant. **(A)** Antimicrobial activity against *C. acnes* C2 is retained and enhanced after butanol extraction of PSMβ from sterile supernatant of *S. capitis* E12 and not with the lantibiotic-producing *S. hominus* A9. **(B)** Silver stain of the total protein content of *S. capitis* E12 supernatant before and after butanol extraction showing enrichment of small PSMβ peptides.

**[0036]** **Figure 11** shows PSMβ does not synergize with host LL-37 antimicrobial peptide. Assessment of synergistic antimicrobial activity against *C. acnes* C2 from *S. capitis* E12 extract and human LL-37 antimicrobial peptide, at indicated concentrations.

#### DETAILED DESCRIPTION

**[0037]** As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents and reference to "the microorganism" includes reference to one or more microorganisms and equivalents thereof known to those skilled in the art, and so forth.

**[0038]** Also, the use of "or" means "and/or" unless stated otherwise. Similarly, "comprise," "comprises," "comprising" "include," "includes," and "including" are interchangeable and not intended to be limiting.

**[0039]** It is to be further understood that where descriptions of various embodiments use the term "comprising," those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language "consisting essentially of" or "consisting of."

**[0040]** Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of

ordinary skill in the art to which this disclosure belongs. Any methods and reagents similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions.

**[0041]** *Cutibacterium acnes* (*C. acnes*; formerly *Propionibacterium acnes*; *C. acnes* and *P. acnes* are used interchangeably herein) is a slow-growing, aerotolerant anaerobic, Gram-positive bacterium linked to skin acne; it can also cause chronic blepharitis and endophthalmitis, the latter particularly following intraocular surgery. Although *P. acnes* is a member of the normal skin commensal bacterial flora, it plays a critical role in the development of inflammatory acne when the microorganism overgrows within the pilosebaceous unit. Inflammatory acne is the most common disease of human skin afflicting up to 80% of individuals through their lives.

**[0042]** As mentioned *C. acnes* plays a critical role in the development of inflammatory acne when the microorganism overgrows within the pilosebaceous unit. Inflammatory acne is the most common disease of human skin afflicting up to 80% of individuals through their lives. Acne has many different symptoms including comedones, papules, pustules, nodules, cysts and pilosebaceous inflammation. Among these, inflammatory lesions of acne are of serious concern to patients because they may lead to acne scarring, thereby inducing adverse psychological effects. The genome of the bacterium has been sequenced and a study has shown several genes can generate enzymes for degrading skin and proteins that may be immunogenic (activating the immune system). This bacterium is largely commensal and part of the skin flora present on most healthy adult human skin. Typically, the organism is just barely detectable on the skin of healthy preadolescents. It lives primarily on, among other things, fatty acids in sebum secreted by sebaceous glands in the follicles. It may also be found throughout the gastrointestinal tract.

**[0043]** Reduction in *P. acnes* survival correlates with clinical improvement of acne in patients. Systemic antibiotics have been used to treat acne for several decades and are still widely prescribed for acne patients. Topical antibiotics are also helpful, and the oxidizing agent benzoyl peroxide (BPO) has been one of the most frequently used topical medications for acne treatment. Topical drug

therapies are often used as the first line treatment for patients suffering from mild to moderate acne. However, current antibiotic treatments have major drawbacks. Systemic antibiotics non-specifically disrupts microbial ecosystem and promote antibiotic resistance. Topical antibiotics are very poor at killing *P. acnes* on the skin surface.

**[0044]** The disclosure demonstrates that coagulase-negative Staphylococci (CoNS) species that normally reside on skin such as *S. epidermidis* and *S. capitis* protect against *C. acnes* by producing factors that inhibit *C. acnes*. The disclosure thus provides prebiotics, probiotics and postbiotics that can be used to treat *C. acnes* infection and/or inhibit *C. acnes* growth.

**[0045]** The disclosure shows, for example, that *S. capitis* E12 constitutively produces antimicrobial peptides in sufficient quantities to kill *C. acnes*. Strikingly, incubation of a 0.6X concentration of *S. capitis* E12 supernatant with a strain of *C. acnes* that is associated with acne resulted in greater than 4 log reduction in survival of the disease-associated bacterium, and complete sterilization of the culture after 24 h. Another attractive feature was that *C. acnes* C2 did not show acquisition of resistance up to 20 generations. The potency and poor capacity to induce resistance from the agents including, for example, PSMs, produced by *S. capitis* E12 is consistent with the mode of action of the  $\alpha$ helix, amphipathic structure of these peptides. Such a structure is common among many antimicrobial peptides, and enables insertion into and destabilization of bacterial membranes. Such a mechanism of direct membrane disruption is ideal for an antimicrobial that works on an epithelial surface.

**[0046]** While the *S. capitis* genome contains a cluster of up to six PSM-encoding genes, PSM $\beta$ 1, 3, 4 and 6 were readily detected by MS analysis of the purified active fractions. Antimicrobial assays with synthetic peptides PSM $\beta$ 1, 4 and 6 revealed greater activity against *C. acnes* when the bacteria were treated with a combination of all three. Likewise, the expected overall charge of each PSM $\beta$  is subtly different, thus likely impacting binding capacity to a hydrophobic column as well as interaction with the bacterial membrane. Individually, the synthetic PSM peptides were far less

potent than the extract. It is contemplated that PSM $\beta$ 2 and PSM $\beta$ 5 may also be secreted by *S. capitis* but eluted in different fractions that were not biologically active by themselves but would increase the activity of PSM $\beta$ 1, 3, 4 and 6. The  $\beta$  class PSMs have been found in other staphylococci and typically number between two and four. However, their exact role has remained elusive and unlike the smaller PSM $\alpha$ , are not thought to be involved in virulence. *S. aureus* contains two  $\beta$ PSMs (PSM $\beta$ 1/2), but neither are reported to be antimicrobial. Other studies have shown other synthetic PSM $\beta$  peptides to be inhibitory against *S. aureus in vitro* but not known to be active against *C. acnes*. Therefore, adopting the present screening approach identified activity that would not have been detectable by using a genetic screening approach alone. The optimum killing efficacy and specificity of the combination, rather than individual peptides, suggests that a therapeutic approach combining multiple PSMs or the live organism itself may be most effective. The disclosure thus shows that the skin microbiome is a valuable resource for discovering new antimicrobials that can be remarkably selective against specific pathogens and valuable in combating skin disease such as acne vulgaris.

**[0047]** The term "contacting" refers to exposing the skin to a topical prebiotic, probiotic and/or postbiotic composition such that the composition can kill or inhibit *C. acnes* on the skin.

**[0048]** As used herein, the term "fermentation extract" means a product of fermenting a probiotic commensal skin bacteria in a culture and under appropriate fermentation conditions. For example, culturing *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3 can produce factors useful for inhibiting *C. acnes* growth and survival. An extract from *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3 can be applied to the skin to inhibit *C. acnes* growth and/or infection, and/or treat acne vulgaris. In some embodiments, the fermentation extract comprises one or more of PSM selected from the group consisting of PSM $\beta$ -1, -2, -3, -4, -5, -6 and any combination thereof.

**[0049]** The terms "inhibiting" or "inhibiting effective amount" refers to the amount of prebiotic, probiotic and/or postbiotic skin

composition comprising, consisting essentially of or consisting of one or more probiotic microorganism and/or fermented medium or extract and/or fermentation by-products (e.g., PSM $\beta$ s) and/or synthetic molecules that is sufficient to cause, for example, inhibition of *C. acnes* growth, proliferation or presence on the skin. The term "inhibiting" also includes preventing or ameliorating a sign or symptoms of a disorder (e.g., acne, sore, and the like).

**[0050]** The term "phenol soluble modulin" or "PSM" refers to a family of protein toxins that are soluble in phenols and that are produced by staphylococcus bacteria. The protein sequences of the PSMs vary. In the present disclosure a set of PSMs are identified that inhibit the growth and viability of *C. acnes*. These PSMs are identified in Fig. 7B (e.g., PSM $\beta$ 1-6). PSMs of the disclosure can be synthesized using a peptide synthesizer or purified from fermentation extracts of cultures using for example, *S. capitis* E12. Alternatively, the disclosure provides the coding sequences for the PSMs of the disclosure. Such coding sequences can be used to generate PSMs by recombinant molecular biology techniques. For example, one of skill in the art can insert the coding sequence of one or more PSMs into an expression vector and then transfect or transform a suitable host cell (e.g., a bacterial cell), with the vector such that that recombinant bacteria cell expressed the one or more PSMs. Such recombinant bacteria cells can be used in a probiotic of the disclosure or can be used to produce a postbiotic (e.g., an extract) suitable for the methods described herein in the treatment of acne.

**[0051]** As used herein, the term "postbiotic", "postbiotic composition" or "topical postbiotic composition" or "postbiotic skin composition" refer to the non-viable bacterial products or metabolic byproducts from the probiotic organism comprising a probiotic commensal skin bacteria fermentation extract and a pharmaceutical carrier. In certain embodiments, the postbiotic comprises at least 2, at least 3, at least 4 of PSM $\beta$ 1, 3, 4, and/or 6.

**[0052]** As used herein, "polynucleotide" refers to a polymer of deoxyribonucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger genetic construct (e.g., by operably linking a promoter to a polynucleotide encoding a peptide

of the disclosure). Numerous genetic constructs (e.g., plasmids and other expression vectors) are known in the art and can be used to produce the peptides of the disclosure in cell-free systems or prokaryotic or eukaryotic (e.g., yeast, insect, or mammalian) cells. By taking into account the degeneracy of the genetic code, one of ordinary skill in the art can readily synthesize polynucleotides encoding the peptides of the disclosure. The polynucleotides of the disclosure (those set forth in the accompanying sequence listing) can readily be used in conventional molecular biology including for the generation of probes, primers and expression constructs.

**[0053]** As used herein a "prebiotic" is a compound or agent that stimulate the growth and or activity of an *S. epidermidis* and/or *S. capitis* organism of the disclosure. For example, a subject afflicted with acne or a *C. acnes* infection can apply a prebiotic to, e.g., their skin such that the prebiotic stimulates the growth and activity of an *S. epidermidis* and/or *S. capitis* of the disclosure. The stimulated growth and activity of the *S. epidermidis* and/or *S. capitis* would thus produce an inhibitory effect on the *C. acnes* infection thereby treating the acne. A prebiotic compound can comprise a polysaccharide, hydrolysate, salt, herbal extract, or any other compound sufficient to foster the growth of an associated probiotic strain (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. lugdunensis* N028\_E7, and/or *S. epidermidis* N018\_F3) when used in combination with that strain, such as yeast hydrolysate in concentrations of less than about 40% (w/w), microcrystalline cellulose in concentrations of less than about 10% (w/w), and/or sucrose in concentrations of less than about 10% (w/w). Other examples of prebiotics that may be adapted for use with cutaneous bacteria include inulin, glucooligosaccharides, isomaltooligosaccharides, lactosucrose, polydextrose, soybean oligosaccharides, and xylooligosaccharides, and those disclosed in Gibson, G.R. and Roberfroid, M, (Eds.) *Handbook of Prebiotics*, CRC press (2008); Roberfroid, M., *J. Nutr.* 137(3):830S-837 (2007) and Slavin, J. *Nutrients* 5(4):1417-1435 (2013), each of which is incorporated herein by reference in its entirety.

[0054] As used herein, the term "probiotic", "probiotic composition" or "topical probiotic composition" or "probiotic skin composition" comprises a probiotic commensal skin bacteria, an attenuated or engineered microorganism that expresses an agent (e.g., at least two or more of the PSM $\beta$  described herein) that inhibits *C. acnes* growth or infection, and a pharmaceutical carrier that maintain the viability of the commensal skin bacteria. In some embodiments, the probiotic comprises a suitable pharmaceutically acceptable carrier for formulation component and contains a probiotic commensal bacteria of the disclosure at a purification of at least 50-80%, 85%, 87%, 90%, 92%, 95%, 98% or 100%.

[0055] In some embodiments, a probiotic composition described herein comprise, consists essential of or consists of a probiotic organism. In further embodiments, the probiotic organism is a bacterium. In further embodiments, the bacterium comprises a component of the normal skin flora. In further embodiments, the bacterium comprises, consists essential of or consists of a strain of *Staphylococcus hominis*. In other embodiments, the bacterium comprises, consists essential of or consists of a strain of *Staphylococcus epidermidis*. In yet another embodiment, the bacterium comprises, consists essential of or consists of *Staphylococcus capitis*. In still another embodiment, the bacterium comprises, consists essential of or consists of *Staphylococcus lugdnensis*. In other embodiments, the probiotic comprises, consists essential of or consists of a mixture of strains. In some embodiments, the mixture of strains comprises, consists essential of or consists of multiple strains of *S. hominis*. In other embodiments, the mixture of strains comprises, consists essential of or consists of multiple strains of *S. epidermidis*. In other embodiments, the mixture of strains comprises, consists essential of or consists of multiple strains of *S. capitis*. In other embodiments, the mixture of strains comprises, consists essential of or consists of multiple strains of *S. lugdnensis* and/or one or more strains of *S. capitis* and/or one or more strains of *S. lugdnensis*. In other embodiments, the mixture of strains comprises, consists essential of or consists of one or more strains of *S. hominis* and one or more strains of *S. epidermidis*. In some embodiments, the

composition comprises, consists essential of or consists of one or more strains in addition to *S. hominis*, *S. epidermidis*, *S. capitis* and/or *S. lugdnensis*. In some further embodiments, the additional strain or strains comprise one or more strains from the genus *Staphylococcus*, *Lactobacillus* or *Lactococcus*. Specific probiotic formulations may comprise, consists essential of or consists of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. lugdnensis* N028\_E7, and/or *S. epidermidis* N018\_F3. Such formulations typically comprise sufficient quantities of bacterial cells as to provide a final density of  $10^3$ - $10^6$  CFU/cm<sup>2</sup> when applied to the skin of a subject. Such formulations may comprise concentrations of from about  $10^4$  to about  $10^7$  CFU/g, or alternatively, from 10 to about  $10^5$  CFU/g, or alternatively, from about  $10^5$  to about  $10^9$  CFU/g. Such formulations may comprise multiple strains of *S. hominis*, *S. epidermidis*, *S. capitis*, and/or *S. lugdnensis*, and may further comprise *Lactococcus lactis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, and/or other such species or strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora. In some embodiments, *S. hominis* (e.g., strains -A12, -C2, -D12, and/or -G1 as set forth in Table A) comprise 100% of the bacterial cells in a formulation. In some further embodiments, an *S. hominis* strain comprises 90-100%, 85-95%, 70-80%, 75-85%, 60-70%, 65-75%, 50-60%, 55-65%, 40-50%, 45-55%, 30-40%, 35-45%, 20-30%, 25-35%, 10-20%, 15-20%, 1-10%, 5-15%, or less than 1% of the bacterial cells in a given formulation, wherein the remainder of the colony forming units are provided by *S. epidermidis*, *S. capitis*, and/or *S. lugdnensis*, or *Lactococcus lactis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, and/or other such strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora. In some embodiments, *S. epidermidis* strains (e.g., -N018-F3, -G6, -C5 and/or -N038F6 as set forth in Table A) comprise 100% of the bacterial cells in a formulation. In some further embodiments, *S. epidermidis* comprises 90-100%, 85-95%, 70-80%, 75-85%, 60-70%, 65-75%, 50-60%, 55-65%, 40-50%, 45-55%, 30-40%, 35-45%, 20-30%, 25-35%, 10-20%, 15-20%, 1-10%, 5-15%, or less than 1% of the bacterial cells in a given formulation, wherein the remainder of the colony

forming units are provided by *S. hominis*, *S. capitis*, and/or *S. lugdnensis*, or *Lactococcus lactis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, and/or other such strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora. In some embodiments, *S. capitis* strain N030-H8 comprise 100% of the bacterial cells in a formulation. In some further embodiments, *S. capitis* comprises 90-100%, 85-95%, 70-80%, 75-85%, 60-70%, 65-75%, 50-60%, 55-65%, 40-50%, 45-55%, 30-40%, 35-45%, 20-30%, 25-35%, 10-20%, 15-20%, 1-10%, 5-15%, or less than 1% of the bacterial cells in a given formulation, wherein the remainder of the colony forming units are provided by *S. hominis*, *S. epidermidis*, and/or *S. lugdnensis*, or *Lactococcus lactis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, and/or other such strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora.

**[0056]** In some embodiments, bacteria other than *S. hominis*, *S. epidermidis*, *S. capitis* and/or *S. lugdnensis* comprise about 50% or less of the bacterial cells in the formulation. In some embodiments said bacteria comprise less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the bacterial cells within a given formulation. In some embodiments, bacteria other than *S. hominis*, *S. epidermidis*, *S. capitis* and/or *S. lugdnensis* may comprise *Lactococcus lactis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus acidophilus*, and/or other such species or strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora. In some embodiments, the formulations can comprise a combination of 2 or 4 of the strains *S. hominis*, *S. epidermidis*, *S. capitis* and/or *S. lugdnensis* in any percentage from about 1%-99% of a particular strain (e.g., about 25% *S. hominis*, 25% *S. epidermidis*, 25% *S. capitis* and 25% *S. lugdnensis*). Any percentage or ratio of any 2 or more (e.g., 2, 3, 4) of the strains showing positive inhibition of *C. acnes* are contemplated herein. In some embodiments, the formulations comprise about 50% *S. capitis* of the strains listed above and about 50% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise about 40% *S. capitis* of the strains listed

above and about 60% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise about 70% *S. capitis* of the strains listed above and about 30% *S. epidermidis*. In some embodiments, the formulations comprise about 30% *S. capitis* of the strains listed above and about 70% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise about 80% *S. capitis* of the strains listed above and about 20% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise about 20% *S. capitis* of the strains listed above and about 80% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise about 90% *S. capitis* of the strains listed above and about 10% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise greater than about 90% *S. capitis* of the strains listed above and less than about 10% *S. epidermidis* of the strains listed above. In some embodiments, the formulations comprise less than about 10% *S. capitis* of the strains listed above and greater than about 90% *S. epidermidis* of the strains listed above.

**[0057]** As used herein, the term "Probiotic Commensal Skin Bacteria" includes a microorganism of the skin microbiome. The probiotic commensal skin bacteria can include a composition of bacterial that inhibits *C. acnes* growth or infection or kills *C. acnes*. In one embodiment, a probiotic commensal skin bacteria comprises one or more bacteria selected from the group consisting of is *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3.

**[0058]** The term "purified" and "substantially purified" as used herein refers to cultures, or co-cultures of microorganisms or of biological agent (e.g. fermentation media and extracts, fractionated fermentation media, fermentation by-products, peptide, polypeptide, gene, polynucleotide etc.) that is substantially free of other cells or components found in the natural environment with which an *in vivo*-produced agent would naturally be associated. The level of purification can vary from about 50-80% pure for a certain microorganism or agent to 100% pure of a certain microorganism or agent.

[0059] The term "therapeutically effective amount" as used herein for treatment of a subject afflicted with a disease or disorder resulting from overgrowth or infection by *C. acnes* means an amount of a prebiotic, probiotic and/or postbiotic skin composition or extract thereof sufficient to ameliorate a sign or symptom of the disease or disorder. For example, a therapeutically effective amount can be measured as the amount sufficient to decrease a subject's symptoms of acne. Typically, the subject is treated with an amount to reduce a symptom of a disease or disorder by at least 50%, 90% or 100%. Generally, the optimal dosage will depend upon the disorder and factors such as the weight of the subject, the type of bacteria, the sex of the subject, and degree of symptoms. Nonetheless, suitable dosages can readily be determined by one skilled in the art.

[0060] As used herein, the term "topical" can include administration to the skin externally, as well as shallow injection (e.g., intradermally and intralesionally) such that a topical probiotic composition described herein comes in direct contact with skin and dermal layer.

[0061] The disclosure provides whole cell preparations comprising a substantially homogeneous or substantially pure preparation of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3. Such a preparation can be used in the preparation of compositions for the treatment of acne, inflammation and microbial infections. Whole cell preparation can comprise *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3. The disclosure also provides fractions derived from such whole cells comprising agents that reduce *C. acnes* growth or viability in the skin.

[0062] The ability of a first bacterial composition (e.g., *S. capitis*) to inhibit the activity of a second bacterial composition (e.g., *C. acnes*) can be determined by contacting, e.g., a probiotic or postbiotic with, for example, a *C. acnes* and measuring the growth or viability of the *C. acnes* before and after contacting the probiotic or postbiotic. Contacting of an organism with a topical probiotic composition of the disclosure can occur *in vitro*, for

example, by adding the topical probiotic or postbiotic composition to a bacterial culture. Alternatively, contacting can occur *in vivo*, for example by contacting the topical probiotic or postbiotic composition with a subject afflicted with a skin disease or disorder.

**[0063]** A probiotic commensal skin bacterial preparation or postbiotic composition can be prepared in any number of ways. In one embodiment, a probiotic commensal skin bacterial preparation is prepared by culturing and isolating a bacterial strain selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof and resuspending the bacterial strain(s) in a suitable carrier. In another embodiment, a postbiotic composition is prepared by culturing a commensal bacterial strain selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof under condition to obtain a fermentation product, obtaining a cell-free preparation of the fermentation extract and combining the extract with a suitable carrier.

**[0064]** Any of a variety of methods known in the art can be used to administer a topical probiotic or postbiotic compositions to a subject. For example, a probiotic or postbiotic skin composition or extract or synthetic preparation of the disclosure may be formulated for topical administration (e.g., as a lotion, cream, spray, gel, or ointment). Such topical formulations are useful in treating or inhibiting microbial, fungal, viral presence or infections or inflammation on the skin. Examples of formulations include topical lotions, creams, soaps, wipes, and the like.

**[0065]** In yet another embodiment, a topical probiotic composition is provided that comprises a plurality of probiotic commensal skin bacteria. When used for the treatment of acne or other skin diseases or disorders associated with increased *C. acne* levels or activity, the composition comprises one or more bacteria that inhibit such *C. acnes* on the skin. In such instances, the probiotic commensal skin bacteria is a coagulase negative *Staphylococcus* sp. In one embodiment, the probiotic commensal skin bacterial is selected from the group consisting of *S. capitis*

N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

**[0066]** In another embodiment, the topical probiotic composition comprises a postbiotic commensal skin bacteria fermentation extract that inhibits *C. acnes* growth or activity on the skin. In various aspects, the bacteria from which the extract is produced comprises *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3.

**[0067]** In accordance with a further embodiment, the topical compositions above can be formulated as a lotion, shake lotion, cream, ointment, gel, foam, powder, solid, paste or tincture.

**[0068]** In another embodiment, a bandage or dressing is provided comprising the topical prebiotic, probiotic and/or postbiotic compositions described above. In various embodiments, a bandage or dressing is provided the major constituents of which includes a matrix and a probiotic commensal skin bacteria that inhibits *C. acnes* on the skin. In various embodiments, a bandage or dressing is provided the major constituents of which includes a matrix and a postbiotic that inhibits *C. acnes* on the skin.

**[0069]** A pharmaceutical composition comprising a probiotic skin composition disclosed herein comprising a commensal bacteria (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3), may be formulated in any dosage form that is suitable for topical administration for local or systemic effect, including emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, dermal patches. The topical formulation comprising a probiotic disclosed herein may also comprise liposomes, micelles, microspheres, nanosystems, and mixtures thereof.

**[0070]** A "pharmaceutically acceptable carrier" is intended to include solvents, dispersion media, coatings, antibacterial and antifungal agents (as needed so long as they are not detrimental to the probiotic commensal bacteria), isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except

insofar as any conventional media or agent is incompatible with the pharmaceutical composition, use thereof in the therapeutic compositions and methods of treatment is contemplated.

Supplementary active compounds can also be incorporated into the compositions.

**[0071]** Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations disclosed herein include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.

**[0072]** A pharmaceutical composition comprising a probiotic may be formulated in the forms of ointments, creams, sprays and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including such as lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, glycerol and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid (see, Remington: The Science and Practice of Pharmacy). These vehicles are emollient but generally require addition of antioxidants and preservatives.

**[0073]** Suitable cream base can be oil-in-water or water-in-oil. Cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the "internal" phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.

**[0074]** Gels are semisolid, suspension-type systems. Single-phase gels contain material substantially uniformly throughout the liquid carrier. Suitable gelling agents include crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, Carbopol<sup>RTM</sup>; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.

**[0075]** In another embodiment, a pharmaceutical composition comprising a prebiotic, probiotic and/or postbiotic disclosed herein, can be formulated either alone or in combination with one or more additional therapeutic agents, including, but not limited to, chemotherapeutics, antibiotics (so long as they do not destroy the probiotic benefits), antifungal-agents, anti-pruritics, analgesics, protease inhibitors and/or antiviral agents.

**[0076]** Topical administration, as used herein, include (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration. Such topical formulations are useful in treating or inhibiting infections of the eye, skin, and mucous membranes (e.g., mouth, vagina, rectum). Examples of formulations in the market place include topical lotions, creams, soaps, wipes, and the like.

**[0077]** Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer may be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active ingredient disclosed herein, a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

**[0078]** Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum

agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; and cellulose, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT, Rohm America, Inc., Piscataway, N.J.); poly(2-hydroxyethyl-methacrylate); polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methylmethacrylate, ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.

**[0079]** If desired, a suitable therapy regime can combine administration of a prebiotic, probiotic and/or postbiotic composition of the disclosure with one or more additional therapeutic agents (e.g., an inhibitor of TNF, an antibiotic, and the like). The peptide(s), other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially. Suitable antibiotics include aminoglycosides (e.g., gentamicin), beta-lactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin. Generally, the antibiotic is administered in a bactericidal amount. A "bactericidal amount" is an amount sufficient to achieve a bacteria-killing concentration in the subject receiving the treatment. In accordance with its conventional definition, an "antibiotic," as used herein, is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms.

Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.

**[0080]** Compositions provided herein can be used concurrently with other antibacterial agents including sulfa drugs such as sulfamethizole, sulfisoxazole, sulfamonomethoxine, sulfamethizole, salazosulfapyridine, silver sulfadiazine and the like; quinoline antibacterial agents such as nalidixic acid, pipemidic acid trihydrate, enoxacin, norfloxacin, ofloxacin, tosufloxacin tosilate, ciprofloxacin hydrochloride, lomefloxacin hydrochloride, sparfloxacin, fleroxacin and the like; antiphthistics such as isoniazid, ethambutol (ethambutol hydrochloride), p-aminosalicylic acid (calcium p-aminosalicylate), pyrazinamide, ethionamide, protionamide, rifampicin, streptomycin sulfate, kanamycin sulfate, cycloserine and the like; antiacidfast bacterium drugs such as diaphenylsulfone, rifampicin and the like; antiviral drugs such as idoxuridine, acyclovir, vidarabine, ganciclovir and the like; anti-HIV agents such as zidovudine, didanosine, zalcitabine, indinavir sulfate ethanolate, ritonavir and the like; antispirocheteles; antibiotics such as tetracycline hydrochloride, ampicillin, piperacillin, gentamicin, dibekacin, kanendomycin, lividomycin, tobramycin, amikacin, fradiomycin, sisomycin, tetracycline, oxytetracycline, rolitetracycline, doxycycline, ampicillin, piperacillin, ticarcillin, cephalothin, cephapirin, cephaloridine, cefaclor, cephalixin, cefroxadine, cefadroxil, cefamandole, cefotoam, cefuroxime, cefotiam, cefotiam hexetil, cefuroxime axetil, cefdinir, cefditoren pivoxil, ceftazidime, cefpiramide, cefsulodin, cefinenoxime, cefpodoxime proxetil, cefpirome, ceftazopran, cefepime, cefsulodin, cefinenoxime, cefinetazole, cefminox, cefoxitin, cefbuperazone, latamoxef, flomoxef, cefazolin, cefotaxime, cefoperazone, ceftizoxime, moxalactam, thienamycin, sulfazecin, aztreonam or a salt thereof, griseofulvin, lankacidin-group and the like.

**[0081]** In yet a further embodiment, a composition (e.g., a prebiotic, probiotic and/or postbiotic composition) provided herein can be combined with one or more steroidal drugs known in the art, including, but not limited to, aldosterone, beclometasone, betamethasone, deoxycorticosterone acetate, fludrocortisone acetate,

hydrocortisone (cortisol), prednisolone, prednisone, methylprednisolone, dexamethasone, and triamcinolone.

**[0082]** In yet a further embodiment, a composition (e.g., a prebiotic, probiotic and/or postbiotic composition) provided herein can be combined with one or more anti-fungal agents, including, but not limited to, amorolfine, amphotericin B, anidulafungin, bifonazole, butenafine, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fenticonazole, filipin, fluconazole, isoconazole, itraconazole, ketoconazole, micafungin, miconazole, naftifine, natamycin, nystatin, oxyconazole, ravuconazole, posaconazole, rimocidin, sertaconazole, sulconazole, terbinafine, terconazole, tioconazole, and voriconazole.

**[0083]** For use in the therapeutic applications described herein, kits and articles of manufacture are also described herein. Such kits can comprise a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass or plastic.

**[0084]** For example, the container(s) can comprise one or more compositions (e.g., a prebiotic, probiotic and/or postbiotic composition) provided herein, optionally in combination with another agent as disclosed herein. Such kits optionally comprise a composition disclosed herein with an identifying description or label or instructions relating to its use in the methods described herein.

**[0085]** The disclosure provides a more selective and potent method for killing and/or inhibiting the growth of *C. acnes*. The disclosure provides strains of skin commensal bacteria that produce selective antimicrobial activity against pathogenic bacterial strains, but not against other members of skin microflora. Therefore, antimicrobial therapy using commensal bacterial strains would selectively kill target strains of microorganisms. The capacity for selective killing of pathogenic bacteria over the normal microflora is highly desirable because it may help to

maintain homeostasis and shape the normal bacterial community. Most skin commensal strains of CoNS produce multiple antimicrobials. In this case, antimicrobial therapy using commensal strains of bacteria would have a low risk of generating a resistant mutant against antibiotics. Because the strains of CoNS provided here are originally isolated from normal human skin, they would be low toxicity to the host. This disclosure may be used as a live bacterial application or as a sterile extract of the bacteria (e.g., fermentation extract) or as purified active protein or as synthetic peptides.

**[0086]** The disclosure provides several coagulase-negative *Staphylococci* (CoNS) strains as well as two *Cutibacterium acnes* (*C. acnes*) strains that are potent antagonists of acne-associated *C. acnes* strains.

**[0087]** Table A provides a plurality of coagulase-negative *Staphylococci* (CoNS) strains that have anti-*P. acnes* activity:

**[0088]** Table A:

Key#	Species	Strain/ Clone ID	Anti- <i>P.acnes</i> activity (ATCC6919)*	Anti- <i>P.acnes</i> activity (ATCC29322)*
1	<i>Staphylococcus epidermidis</i>	NIAMS009-G7	++	++
2	<i>Staphylococcus epidermidis</i>	NIAMS018-F3	+++	+++
3	<i>Staphylococcus warneri</i>	NIAMS025-G2	+	+
4	<i>Staphylococcus epidermidis</i>	NIAMS028-H4	-	-
5	<i>Staphylococcus epidermidis</i>	NIAMS028-C12	-	-
6	<i>Staphylococcus lugdunensis</i>	NIAMS028-E7	+	+++
7	<i>Staphylococcus capitis</i>	NIAMS030-H8	+++	+++
8	<i>Staphylococcus epidermidis</i>	NIAMS034-C1	-	-
9	<i>Staphylococcus epidermidis</i>	AMT1-A9	-	+
10	<i>Staphylococcus hominis</i>	AMT2-A12	-	-
11	<i>Staphylococcus hominis</i>	AMT3-A12	+++	+++
12	<i>Staphylococcus hominis</i>	AMT4-C2	+++	++
13	<i>Staphylococcus hominis</i>	AMT4-D12	+++	++
14	<i>Staphylococcus hominis</i>	AMT4-G1	+++	++
15	<i>Staphylococcus epidermidis</i>	AMT5-G6	+++	+++
16	<i>Staphylococcus epidermidis</i>	AMT5-C5	+++	+++
17	<i>Staphylococcus epidermidis</i>	S.epiA11	-	-
18	<i>Staphylococcus hominis</i>	S.homC2	+++	++
19	<i>Staphylococcus epidermidis</i>	NIAMS037-H2	-	-
20	<i>Staphylococcus epidermidis</i>	NIAMS037-A9	-	-
21	<i>Staphylococcus epidermidis</i>	NIAMS038-A10	-	-
22	<i>Staphylococcus epidermidis</i>	NIAMS038-F6	+++	+++
23	<i>Staphylococcus hominis</i>	S.homA9	++	-
24	<i>Staphylococcus epidermidis</i>	S.epi1457	-	-

[0089] #17 in Table A (*S. epidermidis* A11) has been deposited with the ATCC as accession number PTO-125202; #23 in Table A (*S. hominis* A9) has been deposited with the ATCC as accession number PTA-125203; #24 in Table A was used as a negative control strain which produces no antimicrobial activity. See, Figure 4 for potency of antimicrobial activity against two *P. acnes* strains.

[0090] The disclosure exemplifies 4 strains of CoNS from skin: *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3. A listing of sequences comprising all detected open reading frames from each of the foregoing strains accompanies this disclosure and is incorporated herein for all purposes. Accordingly, the strains of the disclosure (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3) can be identified using various probes and sequencing techniques and the sequence listing provided herein. For example, the strain *S. capitis* N030\_E12 can be identified by

determining whether an isolated *S. capitis* strain expresses one or more of the nucleic acid sequences identified by SEQ ID Nos: 1 to 2377 or produces PSMβ1, 3, 4 and 6 (see, e.g., SEQ ID NOs: 9437, 9441, 9443 and 9447). Similarly, the strains *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3 can be identified by determining whether an isolated *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3 strain expresses one or more of the nucleic acid sequences identified by SEQ ID Nos: 2378 to 4765 (*S. epi* C5); 4766 to 7145 (*S. epi*, G7); or 7146 to 9435 (*S. epi* F3), respectively.

[0091] These strains are attractive candidates for biotherapy as they demonstrated broad antibacterial activity against multiple different strain types of *C. acnes* isolated from healthy and acne skin, but were less potent against other Gram-positive skin commensals and Gram-negatives (Table 1). In addition, two strains of *C. acnes*: *C. acnes*\_UCSD\_HI12 and *C. acnes*\_UCSD\_HI30, which demonstrated potent inhibition of different *C. acnes* strains by radial diffusion assay (Table 2) and in liquid culture (Fig. 3) are also described. The application/contacting of selected CoNS or *C. acnes* strains to the skin target and eliminant *C. acnes*, the etiological agent of acne, and not other skin resident bacteria which may play beneficial role in health.

[0092] **Table 1:** Results of CoNS antagonism towards multiple different bacterial species by radial diffusion assay. Zone of killing/inhibition by radial diffusion: + small ++ medium +++ large

	Rank order for application	1	2	3	4
Sequence type	Bacterial genus, species and strain name	<i>S. capitis</i> N030_E12	<i>S. epidermidis</i> AMT5_C5	<i>S. epidermidis</i> N009_G7	<i>S. epidermidis</i> N018_F3
N/A	<i>S. aureus</i> Newman		+++	++	+++
N/A	<i>S. aureus</i> USA300		+++	++	+++
N/A	<i>S. aureus</i> 113	+++	+++	+++	+++
N/A	Group A <i>Streptococcus</i> NZ131				
N/A	Group B <i>Streptococcus</i> DK23				
N/A	<i>S. hominus</i> 27844	+	+	+	
N/A	<i>S. lugdensis</i>	+			
N/A	<i>S. warneri</i>				
N/A	<i>S. epidermidis</i> 12228	+			
N/A	<i>E. coli</i> RS218				
N/A	<i>P. aeruginosa</i> PA01				
N/A	<i>P. aeruginosa</i> PA4				

N/A	<i>S. Typhimurium</i> 14028				
N/A	<i>A. baumannii</i> AB5075				
<b>Sequence type</b>	<b><i>Cutibacterium acnes</i> strain and site of origin</b>	<b><i>S. capitis</i> N030_E12</b>	<b><i>S. epidermidis</i> AMT5_C5</b>	<b><i>S. epidermidis</i> N009_G7</b>	<b><i>S. epidermidis</i> N018_F3</b>
K1	<i>C. acnes</i> HL042PA3 Health	+++	++	++	+++
K2	<i>C. acnes</i> CRA7 Health	+++			
K1	<i>C. acnes</i> NIKH1 Health	++	+	+	+
A2	<i>C. acnes</i> LNGA1 Health	+++	++	++	++
H1	<i>C. acnes</i> TRUF3 Health	+++			
H1	<i>C. acnes</i> A15NonLesional PA07	+++	++	+	++
C2	<i>C. acnes</i> AI15NonLesional PA03	++	+++	+++	+++
E3	<i>C. acnes</i> AI09NonLesional PA01	+++	+++	+++	++
E3	<i>C. acnes</i> AI09NonLesional PA04	+++	++	++	++
F4	<i>C. acnes</i> Lesional 104.1	+++	+	+	+
C2	<i>C. acnes</i> AI01Lesional PA22	+++	++	++	+++
A1	<i>C. acnes</i> AI15Lesional PA10	+++	++	++	++
C2	<i>C. acnes</i> AI01Lesional PA23	+++	++	+	+

[0093] **Table 2:** Several distinct *C. acnes* strains isolated from skin of healthy individuals (HI) were also found to inhibit the growth of different *C. acnes* strains from both healthy and acne-affected skin. Two distinct strains of *C. acnes*: *C. acnes*\_UCSD\_HI12 and *C. acnes*\_UCSD\_HI30 produced a potent inhibitory product against several strains of *C. acnes*. Both live cultures and sterile supernatant of both strains were found to inhibit the growth of *C. acnes* measured by radial diffusion in agar (**Table 2**) and liquid culture (**Fig. 3**).

C. acnes strains	SLST	Origin	C. acnes UCSD										C. acnes UCSD		(control) S. capitis N030_E12		
			C.a1	C.a2	C.a3	C.a4	C.a6	H12	C.a8	C.a9	C.a10	C.a11	H90	C.a12		C.a13	
C.a30	A1	Health															+++
C.a31	A1	Health															+++
C.a32	H1	Acne											++				+++
C.a33	H1	Acne											++				+++
C.a34	K1	Health							+								+++
C.a35	K1	Health															++
C.a36	K2	Health														+	++
C.a37	K2	Health							+++					+			++
C.a38	C2	Acne							+++					+			++
C.a39	C2	Acne	+											+			++
C.a40	C1	Acne												+			+++
C.a41	C1	Acne												++			+++
C.a42	D1	Health															+++
C.a43	D1	Acne												++			+++
C.a44	F4	Acne							+								+++
C.a45	F1	Health												+			++
S. aureus	113	N/A															+++
S. capitis	E12	N/A															+++

[0094] The four *Staphylococcal* strains included in this disclosure have been sequenced and found to contain several biosynthetic gene clusters encoding predicted non-ribosomal peptide synthetases (NRPSs) and/or polyketide synthases (PKSs). These are major multi-modular enzyme complexes which synthesize secondary metabolites such as antimicrobial peptides, antibiotics and siderophores. Each module of an NRPS cluster activates a different amino or carboxyl acid, followed by their sequential condensation to synthesize a linear or cyclic natural product (see, **Fig. 1**). **Fig. 1** highlights such a NRPS cluster in *S. capitis* N030\_E12 identified by antiSMASH - a comprehensive resource that permits the genome-wide identification, annotation and analysis of secondary metabolite biosynthetic gene clusters in bacterial genomes. The *S. capitis* NRPS cluster contains several genes with specific signature domains potentially involved in synthesis of an antimicrobial peptide such as gramicidin and tyrocidine. **Fig. 2** highlights a *trans*-AT polyketide synthase (PKS) cluster in *S. epidermidis* strains AMT5\_C5, N009\_G7 and N018\_F3 identified by antiSMASH. The PKS machinery contains three essential domains: the acyl transferase (AT), the acyl carrier protein (ACP) and the ketosynthase (KS). For example, some polyketides produced by *Bacillus* species include difficidin and

macrolactin. Therefore, this PKS cluster present within all three *S. epidermidis* species could be a source for novel antimicrobial peptides.

**[0095]** In one embodiment, the disclosure provides a probiotic composition for topical delivery comprising a CoNS commensal skin bacteria of the disclosure (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and/or *S. epidermidis* N018\_F3). In a further embodiment, the topical composition contains only 1, 2, 3 or 4 of the strains selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3. In still another embodiment, a topical probiotic composition of the disclosure can comprise or consist of a commensal skin bacteria selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3, and any combination of the foregoing, wherein the commensal skin bacteria is substantially pure (e.g., 80%, 85%, 87%, 90%, 92%, 95%, 98% or 100% pure of other bacteria species found on the skin of a subject).

**[0096]** In some embodiments, the composition comprises a cream, ointment, oil suspension or unguent wherein the probiotic bacteria (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. lugdnensis* N028\_E7, and/or *S. epidermidis* N018\_F3) as described above are incorporated within a moisturizer or emulsion such as those described below and in Nakatsuji, T. *et al.* (2016), Nature Medicine. In some embodiments, the composition comprises a patch or poultice wherein the bacteria are combined with a suitable excipient and are incorporated within a fabric, gel matrix, or polymer sheet. Suitable excipients and carriers for topical administration are known in the art and include thickeners, emulsifiers, fatty acids, polysaccharides, polyols, and polymers and copolymers, including, without limitation, alginate, microcrystalline cellulose, polylactic acid, polylactic-co-glycolic acid, petrolatum, and numerous others known in the art.

**[0097]** In some embodiments, the composition comprises a bacterial culture medium, a conditioned bacterial culture medium, and/or a bacterial culture. In some embodiments, the composition comprises a filtrate or supernatant of a bacterial culture medium.

In some embodiments, the composition comprises a lyophilized culture medium. In some embodiments, the composition comprises a lyophilized conditioned culture medium produced from a filtrate or supernatant of a bacterial culture medium.

**[0098]** In some embodiments, the method as described herein comprises supporting the health of the skin of a subject. In further embodiments, the method comprises providing a treatment for skin dysbiosis and disorders (e.g., acne) derived therefrom. In some embodiments the method comprises providing a treatment for bacterial infection of the skin (e.g., *C. acne* infection or overgrowth). In some embodiments, the treatment comprises the steps of: identifying a subject with skin dysbiosis, bacterial infection, acne; and administering to the site of the condition in need of treatment the probiotic compositions as disclosed herein. Determination of the appropriate mode of administration of a given formulation (ointment, gel, patch, etc.) can be done by one of ordinary skill in the art of treating skin infections. In some further embodiments, the probiotic compositions are re-applied at regularly timed intervals. In some embodiments, the probiotic compositions are reapplied every three days. In some embodiments, the probiotic compositions are reapplied every two days. In some embodiments, the probiotic compositions are reapplied every two days. In some embodiments, the probiotic compositions are reapplied daily. In some embodiments, the probiotic compositions are reapplied more than once per day. In some embodiments, the probiotic compositions are reapplied weekly. In some embodiments, the probiotic compositions are only applied a single time.

**[0099]** In some embodiments, the method comprises providing a treatment for *C. acnes* infections. In some further embodiments, the method comprises the steps of: diagnosing a *C. acnes* infection; and applying to the site of the infection the probiotic and/or prebiotic compositions as disclosed herein, wherein such compositions are capable of killing or inhibiting the growth of *C. acnes*, either by production of antimicrobial compounds, by competition for resources within the cutaneous or mucosal biota, or by other means. Determination of the appropriate mode of administration of a given formulation (ointment, gel, patch, etc.) can be done by one of

ordinary skill in the art of treating skin infections. In some further embodiments, the probiotic compositions are re-applied at regularly timed intervals (e.g., daily, every two days, every three days, weekly, etc.). It will be apparent to one of ordinary skill in the art that in other embodiments, similar or identical steps can be applied to provide a treatment for *C. acnes*. In some embodiments, the method comprises providing a treatment for infections with unknown or uncharacterized pathogens. In some embodiments, the method comprises providing a treatment for a chronic skin condition.

**[00100]** A commensal bacterial of the disclosure can be isolated from human skin and identified using methods described herein. For example, the disclosure provides a method of obtaining, identifying and culturing a commensal bacteria described herein by swabbing human skin surface using, e.g., a foam tip swab. The swabs were placed in tryptic soy broth. The broth is diluted onto mannitol salt agar plates (MSA) supplemented with 3% egg yolk. Pink colonies without halo representing coagulase-negative *Staphylococci* (CoNS) strains are collected and grown in tryptic soy broth (TSB). The strain can then be assayed as described in **Fig. 4** (see also, **Fig. 5A**). Strains with strong inhibition of *C. acnes* can be further characterized by DNA isolation and sequencing or by PCR, southern or northern blots. In addition, measurement of the expression profile of phenol soluble modulins can also be measured. In some embodiments, organisms expressing PSM $\beta$ 1, 3, 4 and 6 (e.g., SEQ ID NOs: 9437, 9441, 9443, and 9447) can be identified as *S. capitis*. PSM $\beta$  from *S. epidermidis* are provided in SEQ ID NOs: 9449, 9451 and 9453.

**[00101]** gDNA can be isolated using any number of commercially available kits (e.g., DNeasy UltraClean Microbial Kit, Qiagen). The gDNA can be sequenced using various sequence platforms (e.g., MiSeq; Illumina Inc., San Diego, CA for two cycles, which can generate 2x 250 bp paired-end reads). Adapters are removed using cutadapt (see, e.g., world-wide-web at [cutadapt.readthedocs.io/en/stable/](http://cutadapt.readthedocs.io/en/stable/)). Low-quality sequences can be removed using Trim Galore (see, e.g., world-wide-web at [bioinformatics.babraham.ac.uk/projects/trim\\_galore/](http://bioinformatics.babraham.ac.uk/projects/trim_galore/)) with default

parameters. Sequences mapping to the human genome are removed from the quality-trimmed dataset using the Bowtie2 program (ver. 2.28) (*I*) with parameters (-D 20 -R 3 -N 1 -L 20 - very-sensitive-local) and the human reference genome hg19. The filtered reads are *de novo* assembled using SPAdes (version 3.8.0) with k-mer length ranging from 33-127. The genome is annotated with rapid annotation of microbial genomes using subsystems technology (RASY) with default parameters. Predicted amino acid sequences and or the nucleic acid sequences can be compared to the sequence listing attached hereto to identify *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7 and *S. epidermidis* N018\_F3.

**[00102]** The disclosure also provides compositions that comprise at least 2, at least 3, at least 4, at least 5 or at least 6 PSM $\beta$ . In some embodiments, the composition comprises at least 4 PSM $\beta$ . In yet other embodiments the composition comprises at least 5 PSM $\beta$ . In any of the foregoing embodiments, the PSM $\beta$  are selected from PSM $\beta$ 1, 2, 3, 4, 5, and 6. In certain embodiments, the composition comprises at least PSM $\beta$ 1, 3, 4, and 6.

**[00103]** The disclosure also provides formulations for topical administration comprising comprise at least 2 PSM $\beta$ . In some embodiments, the formulation comprises at least 3 PSM $\beta$ . In yet other embodiments the formulation comprises at least 4 PSM $\beta$ . In any of the foregoing embodiments, the PSM $\beta$  are selected from PSM $\beta$ 1, 2, 3, 4, 5, and 6 produced from *S. capitis* E12 and/or having a sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the PSMs set forth in each of SEQ ID NOs: 9437, 9439, 9441, 9443, 9445, 9447. In certain embodiments, the formulation comprises at least PSM $\beta$ 1, 3, 4, and 6. In some embodiments, the formulation comprises at least 3 of PSM $\beta$ 1, 3, 4, and 6 and a probiotic, prebiotic or postbiotic of the disclosure.

**[00104]** The disclosure also provides a method of diagnosing skin dysbiosis and/or risk of a *C. acnes* infection. The method comprises obtaining a biological sample from the skin of a subject and determining the relative abundance of commensal bacteria in the sample, wherein the abundance includes determining the abundance of at least the presence of *S. capitis* and *S. epidermidis*. More particularly, the determining can measure the abundance of at least

1 to 4 (e.g., 1, 2, 3 or 4) of the bacteria selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, and *S. epidermidis* N018\_F3. If the level or abundance of *S. capitis* or *S. epidermidis* (e.g., *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3) falls below a threshold of less than 50%, 40%, 30%, 20%, 10%, 5%, 2.5%, 1%, 0.5%, 0.1% then the subject is at risk of having a *C. acnes* infection.

**[00105]** In another embodiment, the presence of one or more the PSM $\beta$  produced by *S. capitis* E12 can be determine in a sample from the subject in determining if the subject has or is at risk of having a *C. acnes* infection. For example, the sample can be obtained from the skin of a subject, extracted with n-butanol and the presence of PSM $\beta$ s measured as described herein. The presence of PSM $\beta$ 1, 3, 4 and 6 in the sample is indicative of a reduced risk of infection. In contrast no or low levels (levels below a normal average control) is indicative of a subject having or at risk of having a *C. acnes* infection. A "normal" or "average control" level is a level of PSM $\beta$  (e.g., PSM $\beta$ 1, 3, 4, and/or 6) that is the mean level of total PSM $\beta$  or mean level of each type of PSM $\beta$  (e.g., PSM $\beta$ 1, 3, 4 or 6) in a population of subjects that do not have a *C. acnes* infection. In one embodiment a determination of the sequence of each PSM $\beta$  present in the extract sample can be determined and then compared to the sequences as set forth in SEQ ID NOs: 9437, 9439, 9441, 9443, 9445, 9447, to determine which type of PSM $\beta$  is present.

**[00106]** In a further embodiment, the methods of diagnosis and/or prognosis can be used to determine if a subject needs a prebiotic, probiotic or postbiotic therapy as described herein.

**[00107]** The following examples are exemplary and are not intended to limit the claimed invention, but rather illustrate methods of compositions of the disclosure.

#### **EXAMPLE**

**[00108] Human subjects and sample swab collection.** All experiments involving human subjects were carried out according to protocols approved by the University of California, San Diego (UCSD) IRB (Project#140144). Swab sample collection was performed on 12 healthy adults with swabs taken from the upper arm and the face.

Swabs were incubated in 3% Tryptic Soy Broth (TSB), vortexed briefly and plated onto mannitol salt agar containing egg yolk (MAY) plate for selective growth of staphylococcal species. *S. aureus* were distinguished from CoNS according to mannitol metabolism and the egg yolk reaction. *C. acnes* clinical isolates were obtained by swabbing lesional and non-lesional facial skin sites of 10 acne patients as well as facial skin from 6 healthy volunteers. Swabs were incubated in reinforced clostridial media (RCM), vortexed and plated onto brucella blood agar plates supplemented with Vitamin K, hemin and 5% sheeps blood and incubated for 5 days at 37°C.

**[00109] Screening for antimicrobial activity from skin-derived CoNS.** 24 individual isolated colonies of CoNS, that were selected from each skin site, were randomly picked from a MAY plate and transferred to TSB (1 mL) in a deep 96 well plate. Each plate contained a previously characterized CoNS strain, which included *S. epidermidis* ATCC1457 that failed to demonstrate antimicrobial activity against other staphylococci (negative control) as well as *S. hominus* A9 which was previously demonstrated to produce lantibiotics that kill *S. aureus* (positive control). The CoNS plate was sealed with sterile Aeraseal film (sigma) and cultured at 37°C overnight, shaking at 250 rpm. Bacterial growth was evaluated by measuring OD<sub>600</sub> and only CoNS grown to a high density (OD<sub>600</sub>>6.0) were used for subsequent analysis. To measure antimicrobial activity in the secreted supernatant, the CoNS supernatant from overnight culture was harvested and sterile filtered. To measure antimicrobial activity from live growing CoNS, bacteria from overnight culture were pelleted by centrifugation then the supernatant was discarded, and the bacteria were resuspended in fresh TSB.

**[00110] Mass spectrometry.** A portion of the fractions of interest (< 1 µg) were dried under vacuum and resuspended in 5 µL of 5% acetonitrile with 5% formic acid. Next, individual LC-MS experiments were conducted on 1/5 of each sample through 85 minutes of data acquisition on an Orbitrap Fusion (Thermo Fisher Scientific) mass spectrometer with an in-line Easy-nLC 1000 (Thermo Fisher Scientific). A home-pulled and packed 30 cm column was triple-packed with 0.5 cm, 0.5 cm and 30 cm of 5 µm C4, 3 µm C18, and 1.8 µm C18 respectively and heated to 60 °C for use as the analytical column.

Peptides were first loaded at 500 bar which was followed by a chromatography gradient ranging from 6 to 25% acetonitrile over 70 minutes followed by a 5-minute gradient to 100% acetonitrile, which was held for 10 minutes. Electrospray ionization was performed by applying 2000V through a stainless-steel T-junction connecting the analytical column and Easy-nLC system. Each sample was followed by two washes starting with a gradient from 3 to 100% acetonitrile over 15 minutes with an additional 10 minutes at 100% acetonitrile. An m/z range of 375-1500 was scanned for peptides with charge states between 2-6. Centroided data was used for quantitation of peaks. Acquisition was run in a data-dependent positive ion mode. Raw spectra was searched in Proteome Discoverer Version 2.1 against a uniprot reference database for *Staphylococcus capitis* (Uniprot proteome UP000042965, accessed 10/01/2018) using the Sequest algorithm alongside a reverse database approach used to control peptide and protein false discoveries to 1%. No enzyme was specified in the search and a minimum peptide length was set to 6 amino acids. Search parameters included a precursor mass tolerance of 50 ppm and fragment mass tolerance of 0.6 Da and variable oxidation for modifications.

**[00111] *In vitro* antimicrobial assays.** For the initial CoNS antimicrobial screen, the radial diffusion agar assays were performed using *S. aureus* 113 or either *C. acnes* HL110PA3 (health-associated, SLST K1) or *C. acnes* HL096PA1 (acne-associated, SLST C2). For the radial diffusion agar assays, melted TSB or RCM agar (12 mL) was mixed with *S. aureus* or *C. acnes* ( $1 \times 10^6$  CFU) and poured into a 10 cm square petri square. When the agar was solidified, a 10  $\mu$ l aliquot of bacteria was inoculated onto a single grid. The plates were incubated at 37°C overnight shaking (for *S. aureus*) or incubated at 37°C for 3 days in a 2.5L anaeroPack (thermo Scientific) (for *C. acnes*) to allow visible growth of bacteria. Antibacterial activity was indicated by a clear zone of inhibition within the agar that surrounds the colony. The size of the inhibitory zone was recorded as a measure of antimicrobial activity (+ slight, ++ moderate, or +++ potent). For the liquid culture assay, conditioned supernatant from overnight cultures of CoNS were harvested and sterile filtered (0.22  $\mu$ m). 50% of conditioned

supernatant was mixed with 50% fresh TSB or RCM containing  $1 \times 10^5$  CFU/mL of *S. aureus* or *C. acnes*, in a 96 well round bottom plate. *S. aureus* plates were incubated at 37°C shaking overnight and *C. acnes* plates incubated standing at 37°C in an anaerobic chamber. Bacterial growth was measured by OD<sub>600</sub> and positive antimicrobial strains were identified as those that suppressed bacterial growth to less than 50% (I<sub>50</sub>) of growth measured for negative control strains. Bacterial survival was measured by counting the number of CFU on TSB plates (*S. aureus*) or Brucella blood agar plates (*C. acnes*). At selected times post-treatment with bacterial supernatant or extracts, the number of CFU was determined by serial dilution in phosphate-buffered saline (PBS) and plating onto appropriate agar media. Bacterial survival was measured as the total number of CFU per milliliter.

**[00112] Purification of antimicrobials produced by CoNS strains.**

Conditioned media from overnight cultures of the selected antibacterial *S. capitis* E12 strain, including positive control antimicrobial *S. hominus* A9 strain, were first sterilized by filtration through a 0.22µm Millipore filter. Initial characterization involved treating the sterile bacterial supernatant to boiling at 100°C for 15 mins or incubation with proteolytic enzymes papain and proteinase K, at 200 µg/mL at 37°C for 60 mins. Antimicrobial activity was measured by radial diffusion assay. For size exclusion of the antimicrobial molecule, 20 mL of conditioned media was loaded onto a 3, 10 and 30 kDa molecular weight cutoff (MWCO) columns (Pierce) and centrifuged at 4000 x g for 15 mins. Whilst the flow-through fraction was set aside, and the retained fraction was washed 2X in PBS and resuspended with 20 mL TSB. Antimicrobial activity was assessed for both fractions. To precipitate the active molecule, ammonium sulphate was added to the sterile supernatant (30-80% saturation) for 1 hour under constant rotation at room temperature, followed by centrifugation at 4000 x g for 45 mins. The resulting pellet was washed 3X with H<sub>2</sub>O and reconstituted in H<sub>2</sub>O. Antimicrobial activity was determined by *S. aureus* and *C. acnes* growth in agar and liquid culture.

**[00113] Solid Phase Extraction (SPE) and HPLC purification of supernatant.** *S. capitis* E12 sterile supernatant that had been

retained on a 10 kDa MWCO column and precipitated in 60% AS was applied on an Oasis HLB cartridge (Waters). The cartridge was washed in 20% acetonitrile in H<sub>2</sub>O and eluted in 80% acetonitrile in H<sub>2</sub>O. The eluted fractions were lyophilized and reconstituted in H<sub>2</sub>O. The 80% fraction was then loaded onto a C8 Sep-Pak cartridge (Waters), washed in 20% acetonitrile and eluted in 50% acetonitrile. The fractions were lyophilized, reconstituted in H<sub>2</sub>O and then assessed for antimicrobial activity and visualized by silver stain (Pierce) according to manufacturer's instructions. First step HPLC purification was carried out with 1 mg of *S. capitis* E12 butanol extract loaded into a CapCel Pak C8 (5 μm, 300 Å, 4.6 × 250mm) (Shiseido Co.) with a linear gradient of acetonitrile from 10% to 60% in 0.1% (v/v) TFA at 0.8 mL/min. Fractions were lyophilized then resuspended in H<sub>2</sub>O and antimicrobial activity assessed by liquid culture assay. Up to five sequential purifications were carried out with each single antimicrobial fraction pooled together for second step HPLC. For the second purification, a linear gradient of acetonitrile from 25% to 50% was adopted.

**[00114] Transplantation of antimicrobial CoNS on pigskin and mice.** All experiments involving live animal work were in accordance with the approval of the Institutional Animal Care and Use Guidelines of the University of California, San Diego. Fresh-frozen pig skin sheets were obtained from Loretta Tomlin Animal Technologies (Livermore, CA) and sanitized by surgical brush with 3% chloroxylenol. The skin sheet was cut into 2.5cm × 2.5cm and rinsed 20X times with sterile PBS more. 1x10<sup>7</sup> CFU *C. acnes* (ATCC6919) was epicutaneously challenged on pig skin for 1 hour and 100 μl of *S. capitis* E12 extract (10 mg/mL) or PBS control was applied for 24 h. Live bacteria were harvested by swabbing to measure *C. acnes* survival. For mouse experiments, the backs of hairless SKH1 mice were scrubbed with alcohol wipes and 1x10<sup>7</sup> CFU *C. acnes* was inoculated onto sterile gauze pads which were placed onto the dorsal skin and secured with tegaderm film for 24 h. *C. acnes*-containing gauze pad was removed and 100 μl of *S. capitis* E12 extract (10 mg/mL) or PBS control was inoculated onto fresh gauze pad and placed back onto the same dorsal skin site and secured with tegaderm film

for an additional 24 h. 48 h post-inoculation, skin was swabbed to measure surviving CFU of *C. acnes*.

**[00115] Screening for antimicrobial activity from human skin bacteria identifies a *S. capitis* strain with potent and selective activity against *C. acnes*.** A library of 288 CoNS isolates were collected from skin swabs of the forearm and face of healthy volunteers. An unbiased analysis of anti-*C. acnes* activity was performed by live coculture with the CoNS isolate growing on agar with *C. acnes* and measuring the growth of *C. acnes* following the addition of 50% v/v conditioned CoNS supernatant that was sterile filtered (**Fig. 5A**). Results of the functional screen revealed a total of 13 isolates that were active against the growth of *C. acnes* in both the liquid assays and agar coculture (**Fig. 5B,C**). DNA extracted from the CoNS isolates with antimicrobial activity was subjected to 16S sequencing and several different species were identified, including *S. epidermidis* and *S. hominis* which are considered frequent colonizers of human skin. The most potent isolate was identified as *Staphylococcus capitis* (*S. capitis* strain E12) and was used for further characterization. Of the 13 antimicrobial strains identified, all were isolated from the forearm. None of the facial isolates were found to inhibit the growth of *C. acnes*. Interestingly, the lantibiotic-producing *S. hominus* A9 strain that is active against *S. aureus* was ineffective against *C. acnes*, illustrating the selective nature of antimicrobials derived from the mixed bacterial community of the skin.

**[00116]** Next, the selectivity of *S. capitis* E12 to inhibit the growth of several different CoNS commensal species and common skin pathogens was tested by agar assay. Whilst the *S. hominus* A9 potentially inhibited the growth of *S. aureus* and GAS, *S. capitis* E12 exhibited only weak activity against CoNS and was ineffective against other skin pathogens (**Fig. 5D**). Strikingly, *S. capitis* E12 exhibited potent activity against a wide range of *C. acnes* strains, including strains that were isolated from either lesional or non-lesional skin of acne patients. 50% dilution of unconcentrated media sterile supernatant from *S. capitis* E12 was sufficient to inhibit *C. acnes* growth, thus validating the findings from the functional screen and demonstrating that under normal growth conditions this

strain of *S. capitis* can produce sufficient antimicrobial activity to outcompete *C. acnes* (**Fig. 5E**). To investigate if the antimicrobial supernatant is bactericidal, the number of surviving *C. acnes* colonies was enumerated after 24 h treatment with increasing concentrations of *S. capitis* E12. Consistent with results from the functional screen, *S. capitis* supernatant was generally not bactericidal against other CoNS species, with exception to the *S. hominus* strain 27844 only at the highest 10X concentration. However, the *S. capitis* E12 supernatant was bactericidal against *C. acnes*, showing a 6-log decrease of *C. acnes* during exposure to 0.6X (60%) supernatant and complete sterilization of the culture at highest concentrations (**Fig. 5F**).

**[00117] Purification and identification of PSM $\beta$  antimicrobial peptides.** Initial examination into the nature of the antimicrobial factor revealed it to be resistant to heat treatment, but sensitive to proteolysis, suggestive of a proteinaceous molecule (Suppl. Fig.1A,B). Furthermore, the antimicrobial factor was precipitated from supernatant during incubation with 60-80% ammonium sulphate (AS) and concentrated by centrifugation (**Fig. 9C**). Next, sample preparation was carried out on the concentrated AS precipitate using solid phase extraction. Samples were first loaded onto a hydrophilic-lipophilic balanced (HLB) column and the anti-*C. acnes* molecule was found to be eluted at 80% acetonitrile, as determined 72 h after inoculation onto *C. acnes* agar (**Fig. 6A**) or with *C. acnes* in liquid culture (**Fig. 6B**). The active elution was subsequently loaded onto a hydrophobic C8 cartridge and the anti-*C. acnes* molecule was eluted at 50% acetonitrile (**Fig. 6A,B**). Total protein staining of the fractions revealed a highly enriched band(s) of roughly 4-5 kDa in size, with greater purity visible during subsequent elution steps (**Fig. 5C**). Reverse phase high performance liquid chromatography (HPLC) revealed several peaks, of which a single fraction (fraction 21) was found to suppress the growth of *C. acnes* in liquid culture (**Fig. 5D**). To ensure the highest purity, the active fractions were then pooled together from four separate HPLC runs and a second step HPLC purification was performed. This time, several small peaks were visualized (**Fig. 6F**), and two fractions (fractions 15 and 16) were found to suppress the growth of *C. acnes*

in liquid culture (**Fig. 6G**). Mass spectrometry (MS) analysis of active fractions (15,16) and control non-active fractions (13,14,17,18) revealed four candidate peptides referred to as "antibacterial protein" each 5 kDa in size (**Fig. 6H**). BLAST search of the peptide sequences identified these as belonging to the beta class family of phenol soluble modulins (PSM $\beta$ ) present within multiple *Staphylococcal* species.

**[00118]** Whilst 4 distinct PSM $\beta$  peptides were detected by MS, analysis of the *S. capitis* E12 genome revealed up to 6 PSM $\beta$ -encoding genes, contained within an operon-like structure (**Fig. 7A**). All six PSM $\beta$ -encoding genes are closely related, with amino acid sequence identity ranging from 56% to 91%, and predicted charge ranging from -1 to +1 (**Fig. 7B**). Further analyses found these genes to be absent from genomes of ATCC strains of *S. capitis* 35661 and 27844 and indeed no antimicrobial activity was detected against *C. acnes* from these laboratory strains (**Fig. 7C**). Alpha helical wheel plots (Heliquest) also predicted these peptides to form an  $\alpha$ -helix, amphipathic-like structure for each PSM $\beta$ , with separate hydrophobic and hydrophilic faces on the opposite sides of the long axis of the peptide. This amphipathic structure is common amongst many well characterized antimicrobial peptides (**Fig. 7D**).

**[00119]** **PSM $\beta$  inhibits skin colonization by *C. acnes*.** *S. capitis* E12 conditioned supernatant was extracted with n-Butanol, a procedure that enriches for PSM peptides. This resulted in a relatively pure extract enriched for all PSM $\beta$  peptides, and retained activity against *C. acnes* (**Fig. 10**). To confirm that PSM $\beta$  peptides were active as the anti-*C. acnes* molecule, and identify which peptide had optimal activity, PSM $\beta$ 1 and 6, the most abundant molecules from the purified active fractions (15 and 16, **Fig 6H**), as well as PSM $\beta$ 4, which was less abundant, were individually synthesized. All three PSMs were shown to possess antimicrobial activity *in vitro* (**Fig. 8A**). PSM $\beta$ 1 and 6 both effectively inhibited growth of *C. acnes* at 62  $\mu$ g/ml, whilst PSM $\beta$ 4 was less potent, inhibiting at 125  $\mu$ g/ml. Interestingly, the combination of all three peptides exhibited optimal activity against *C. acnes*, inhibiting growth in 31  $\mu$ g/ml. However, this was not as inhibitory compared to the same concentration of the butanol extract, which inhibited at 8

µg/ml. This discrepancy could be due to the presence of the additional fourth PSMβ peptide (PSMβ3) found within the extract. Several bacterial antimicrobials have been shown to synergize with human antimicrobials such as defensins and LL37. However, exposure of *C. acnes* to *S. capitis* extract with or without LL-37 peptide did not result in enhanced killing activity (**Fig. 11**). Given the greater potency and relative purity of the PSMβ-containing extract compared to the synthetically produced PSMβ peptides, the extract was used in subsequent experiments to determine the efficacy and potency of *S. capitis* E12 *in vitro* and *in vivo* experiments.

**[00120]** *S. capitis* E12 extract was next compared to several antibiotics commonly used for acne treatment. The extract was more potent against *C. acnes* than erythromycin, clindamycin and tetracycline, antibiotics which are commonly prescribed for acne treatment (**Fig. 8B**). Moreover, no increase in the MIC ( $\leq 16$  µg/mL) was recorded for *C. acnes* during treatment with the extract for up to 20 generations, indicating relative inability to promote resistance. Furthermore, exposure of primary human keratinocytes (NHEKs) to extracts did not produce a significant cytotoxic response from these epidermal cells as measured by lactate dehydrogenase (LDH) release (**Fig. 8C**). Likewise, mouse back skin exposed to different strains of CoNS for 24 h showed that *S. capitis* E12 did not induce observable erythema or injury (**Fig. 8D**). Finally, having confirmed the expected result that this commensal skin bacterium was well tolerated by the epidermis, *C. acnes* was epicutaneously applied to colonize pig skin *ex vivo* or back skin of live SKH1 mouse, and then extract from *S. capitis* E12 was applied. A single treatment resulted in a significant reduction in *C. acnes* CFU in both models (**Fig. 8E,F**). Overall, these results demonstrate PSMβ from *S. capitis* E12 has capacity to kill *C. acnes* and illustrates the potential of exploiting naturally occurring microbial events in the human skin for development of therapeutics.

**[00121]** A number of embodiments of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other embodiments are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A topical probiotic composition comprising, consisting essentially of or consisting of a microorganism selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

2. A postbiotic composition comprising a fermentation extract of a probiotic composition of claim 1.

3. A pharmaceutical composition comprising a probiotic of postbiotic of claim 1 or 2 and a pharmaceutically acceptable carrier.

4. A composition comprising a thickened topical formulation of one or more probiotic bacterial strains and optionally, a prebiotic compound, a protectant, humectant, emollient, abrasive, salt, and/or surfactant;

wherein the one or more probiotic bacterial strain comprises one or more bacterial strains are selected from the group consisting of *S. capitis*, *S. epidermidis* and any combination thereof;

wherein the composition is formulated for the topical treatment of disorders of dysbiosis of the skin, scalp, or mucosae; and

wherein the composition inhibits the growth of *C. acnes*.

5. The composition according to claim 4, wherein the one or more probiotic bacterial strain are selected from the group consisting of *S. capitis* N030\_E12, *S. epidermidis* and any combination thereof.

6. The composition according to claim 5, wherein the one or more probiotic bacterial of *S. epidermidis* are selected from the group consisting of *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

7. The composition according to claim 5, wherein one or more probiotic bacterial strains comprises *S. capitis* N030\_E12, *S.*

*epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and any combination thereof.

8. The composition according to claim 5, wherein each probiotic bacterial strain inhibits *C. acnes* growth.
9. The composition according to claim 4, wherein the one or more probiotic bacterial strains is provided in a live form.
10. The composition according to claim 4, wherein the one or more probiotic bacterial strains is provided in a lyophilized or freeze-dried or spray dried form.
11. The composition according to Claim 10, wherein the probiotic bacterium can be reconstituted into a live form.
12. A method of treating skin or mucosal infections, atopic dermatitis, psoriasis, mastitis, acne, or other disorders related to skin dysbiosis in humans or other mammals by applying to the skin or mucosa an effective amount of the composition of any of claims 4-11 to a subject in need thereof.
13. The method according to claim 12, wherein the composition is applied topically.
14. The method according to claim 13, wherein the composition is formulated as a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.
15. A method of treating a dermatological disorder associated with *C. acnes* comprising administering an effective amount of a composition of any one of claim 1, 2 or 4-11 or pharmaceutical composition which inhibits *C. acnes* growth, viability or activity.
16. The method of claim 12, wherein the dermatological disorders is selected from the group consisting of acne, chronic blepharitis and endophthalmitis.

17. The method of claim 12, wherein the administering is by topical application.
18. A topical composition consisting of one or more bacteria selected from *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 and a carrier.
19. The topical composition of claim 18, wherein the carrier forms a lotion, tincture, cream or ointment.
20. A composition comprising a cell-free fermentation extract obtain a culture of *S. capitis* N030\_E12, *S. epidermidis* AMT5\_C5, *S. epidermidis* N009\_G7, *S. epidermidis* N018\_F3 or any combination thereof.
21. A pharmaceutical composition comprising a composition of claim 20 and a pharmaceutically acceptable carrier.
22. A formulation for topical application comprising a composition of claim 20 and a pharmaceutically acceptable carrier.
23. The composition of claim 20 or 21 or the formulation of claim 22, wherein the composition or formulation comprises a plurality of phenol soluble modulins (PSM).
24. The composition or formulation of claim 23, wherein the PSM is a PSM selected from the group consisting of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof.
25. The composition or formulation of claim 24, wherein the composition or formulation comprises PSM $\beta$ 1, 3, 4 and 6.
26. The formulation of claim 25, wherein the formulation comprises a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.

27. A method of treating a dermatological disorder associated with *C. acnes* comprising administering an effective amount of a composition or formulation of any one of claim 20-26 or which inhibits *C. acnes* growth, viability or activity.

28. A method of diagnosing a skin disease or disorder comprising measuring the amount of PSM $\beta$  in a sample from the skin of a subject, wherein the measurement determines the level of PSM selected from the group consisting of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof and comparing the levels to a normal control level of PSM $\beta$ 1, PSM $\beta$ 3, PSM $\beta$ 4, PSM $\beta$ 6 and any combination thereof, wherein a level that is lower in the sample is indicative of a skin disease or disorder.

29. The method of claim 28, wherein the skin disease or disorder is a *C. acnes* infection.




FIG. 1A-B





FIG. 2A-B



2 / 16




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C

Strain	Skin pathogens and commensal species	S. capitis N030_E12	S. hominus A9	SLS type	C. acnes isolates & site of Origin	S. capitis N030_E12	S. hominus A9
Newman	S. aureus		+++	K1	C. acnes Health	+++	
USA300	S. aureus		+++	K2	C. acnes Health	+++	
NZ131	Group A Streptococcus		+++	K1	C. acnes Health	++	+
DK23	Group B Streptococcus		+++	A2	C. acnes Health	+++	
27844	S. hominus	+		H1	C. acnes Health	+++	
UCSD1	S.lugdunensis	+		H1	C.acnes nonlesional	+++	
UCSD1	S. warneri			C2	C.acnes nonlesional	++	
12228	S. epidermidis	+		E3	C.acnes nonlesional	+++	
RS218	E. coli			E3	C.acnes nonlesional	+++	
PA01	P. aeruginosa			F4	C. acnes lesional	+++	
PA4	P. aeruginosa			C2	C. acnes lesional	+++	
14028	S. typhimurium			A1	C. acnes lesional	+++	
AB5075	A. Baumannii			C2	C. acnes lesional	+++	

FIG. 5D

5 / 16




FIG. 5E




FIG. 5F

6 / 16




FIG. 6A




FIG. 6B

7 / 16




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G

Accession	Protein description	Coverage	Peptides	Size	Fract. 13	Fract. 14	Fract. 15	Fract. 16	Fract. 17	Fract. 18	Score
A0A0S4MC59	Antibacterial protein 3 homolog (PSMβ6)	100	9	5		3.50E+06	1.60E+07	3.70E+06	2.00E+06	3.10E+06	33
A0A0U1EEI2	Uncharacterized protein	87	5	3					9.80E+06	2.70E+06	24
A0A0S4MAE4	Antibacterial protein 1 homolog (PSMβ4)	80	5	5		1.90E+07	2.50E+07	7.50E+05		1.60E+06	48
A0A0S4M5TD	Antibacterial protein 1 homolog (PSMβ3)	82	6	5		7.00E+06	1.00E+06				23
A0A0U1E2B3	Uncharacterized protein	34	3	7					2.40E+06	8.60E+05	10
A0A0S4MFS8	Antibacterial protein 2 (PSMβ1)	50	3	5			3.70E+06	3.60E+06	1.20E+06		5
A0A0S4MEM2	Immunodominant antigen B	11	2	20	1.60E+07	2.00E+06	5.80E+06	3.70E+06		1.80E+05	26
A0A0U1E7C6	Elongation factor G	2	1	76	3.90E+06	6.40E+05					5

FIG. 6H

10 / 16




FIG. 7A

	10	20	30	40	
PSMβ1:	MTKLAEAI	ANTVKAGQDHDWAK	LGTSIVGIAENGI	GLLGKVFEGF	+1
PSMβ2:	MTKLAEAI	ANTVKAGQDHDWAK	LGTSIVGIAENGI	GALSKIFGG	+1
PSMβ3:	MQKLAEAI	ANAVKAGQDHDWAK	LGTSIVGIAENGI	NAITKIFGG	+1
PSMβ4:	MTKLAEAI	ANAVKAGQDHDWAK	LGTSIVGIAENGI	SLLGKVFEGF	0
PSMβ5:	MQKLAEAI	ANTVKAGQDHDWTK	LGTSIVDIVE	NGVSALTKVFEGG	0
PSMβ6:	MEKLFDAIR	NTVDAGINQDWTK	LGTSIVDIVE	NGVKVISKFIGA	-1
	* * *	* * * * *	* * * * * * * * *	* * * * *	* * *

FIG. 7B




FIG. 7C

PSMβ1 (aa 1-44)




FIG. 7D




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F

13 / 16





FIG. 9A

Papain  
Proteinase K  
Untreated



*S. hominus* A9

*S. capitis* E12

*S. capitis* 10kDa Retain

FIG. 9B




FIG. 9C




FIG. 10A

15 / 16




FIG. 10B




FIG. 11

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/51156

## A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 35/74, 8/99, 9/06; A61P 17/10 (2019.01)

CPC - A61K 35/74, 8/99, 9/06; A61P 17/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y -- A	WO 2016/179440 A2 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 10 November 2016; abstract; paragraphs [0011], [0014], [0034], [0052], [0061], [00111], [00117], [00119]; claims 8-12, 20-21	1-2, 3/1-2, 4-11, 12/4-11, 13/12/4-11, 14/13/12/4-11, 15/1-2, 15/4-11, 16/12/4-11, 17/12/4-11, 18-22, 23/20-22 ----- 24/23/20-22 ----- 25/24/23/20-22, 26/25/24/23/20-22, 28-29
Y	(BHATIA, A et al.) Propionibacterium Acnes And Chronic Diseases. The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary. Washington (DC): National Academies Press (US); 2004; retrieved from the internet <a href="https://www.ncbi.nlm.nih.gov/books/NBK83685/?report=printable">https://www.ncbi.nlm.nih.gov/books/NBK83685/?report=printable</a> ; pages 1-6; page 1/6, paragraphs 1, 4	4-11, 12/4-11, 13/12/4-11, 14/13/12/4-11, 15/1-2, 15/4-11, 16/12/4-11, 17/12/4-11
Y -- A	(LI, S et al.) Phenol-Soluble Modulins: Novel Virulence-Associated Peptides of Staphylococci. Future Microbiology. 03 December 2013; Vol. 9, No. 2; pages 203-216; page 204, column 1, paragraph 3; table 1; figure 2B; DOI: 10.2217/fmb.13.153	24/23/20-22 ----- 25/24/23/20-22, 26/25/24/23/20-22, 28-29
A	WO 2015/097061 A1 (BRUKER DALTONIK GMBH) 02 July 2015; claim 1	25/24/23/20-22, 26/25/24/23/20-22, 28-29

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application  
"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

01 November 2019 (01.11.2019)

Date of mailing of the international search report

19 NOV 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/51156

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 27  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.